Introduction
Intracranial aneurysm (IA) is a complex disease characterised by pathological dilatation of the cerebral arteries. IA may rupture, leading to subarachnoid haemorrhage (SAH) and significant morbidity and mortality, one of the most devastating neurological events.1 Although the pathogenesis of IA has been explored for many years, the mechanisms of its formation, growth, and rupture remain largely unknown. Various theories have been proposed to develop IA, which is generally believed to be a multifactorial disorder that occurs due to the interaction of environmental and genetic factors.2,3 Environmental factors, such as alcohol consumption, smoking, sex, and hormonal background of the patient, and hypertension seem to be common risk factors.4,5 In addition, there have been many studies on genetic markers for the risk of IA,6,7 which vary according to ethnicity and may not be generalisable to different populations.
Extracellular matrix (ECM) remodelling plays an important role in maintaining the structure and integrity of intracranial arteries. Disruption of the ECM of the arterial wall is a likely factor in the pathogenesis of IA.8 The VCAN gene, located at 5q12-q14, has 15 exons encoding a large 372.82 kDa chondroitin sulphate proteoglycan in the ECM, which plays a key role in maintaining ECM function.9 It has also been implicated in cell proliferation, cell adhesion, cell migration, and invasion. The VCAN gene produces four subtypes, V0, V1, V2, and V3, by alternate splicing of exons 7 and 8. The two largest exons, 7 and 8, encode glycosaminoglycan (GAG) attachment sites, GAG alpha and GAG beta, respectively.9,10 The latter contains a proteoglycan class with heparin sulphate. The loss of function of similar protein-binding domains may lead to the rupture of these components in certain proteins in the ECM, softening the artery wall, forming an aneurysm.
VCAN is a candidate gene for IA because it plays a vital role in ECM assembly and is localised in a previously implicated locus for IA on chromosome 5q.11 However, polymorphisms can have various effects in these gene regions that can be race-specific (since polymorphisms are known to be race-specific). Previous linkage studies have indicated that the three VCAN SNPs, rs251124, rs173686, and rs2287926, are associated with aneurysms.10,12,13 Nevertheless, replication studies in different ethnicities have provided conflicting results regarding IAs.10,12,14,15 Considering the genetic differences among different races and regions and the uncertainty of the correlation between VCAN gene polymorphism and IA incidence in the Chinese population, we aimed to explore the association of the VCAN gene variants rs251124, rs173686, and rs2287926 with IA prevalence in the Eastern Chinese population.
This study complied with the tenets of the Declaration of Helsinki and was approved by the Institutional Review Board and Ethics Committee of the First Affiliated Hospital of Anhui University of Science and Technology. All participants provided written informed consent (Approval No. 2019B20,2019-1-1).
This case-controlled prospective study included 162 patients with sporadic IAs and 182 age-matched controls admitted to the First Affiliated Hospital of Anhui University of Science and Technology between January 2017 and December 2020. All cases with confirmed IAs based on digital subtraction angiography (DSA) were retrospectively confirmed by a neuroradiologist and two highly qualified cerebrovascular neurosurgeons. Patients were excluded if they had a family history of IA, fusiform and dissection aneurysms, or traumatic and infectious aneurysms. A total of 182 controls were symptomatically normal and did not have a medical or family history of IA or SAH. Controls subjects were sex- and age-matched individuals, diagnosed negative for IA by DSA or CTA from the same hospital, and matched to IA patients for the area of residence to eliminate the effect of population stratification by heterogeneity.
Candidate SNPs were selected by searching for SNPs in previous studies and genome-wide association studies (GWAS) that showed significant associations with IA. DNA was extracted from peripheral blood leukocytes using the TIANamp Blood DNA Extraction Kit (TIANGEN Biotech Co., Ltd., Beijing, China). The DNA samples were stored at 80 C until use. SNP genotyping for rs251124, rs2287926, and rs173686 was performed using Kompetitive Allele Specific PCR (KASP). The SNP data were analysed with CFX Manager Software version 3.1 (Bio-Rad).
General clinical features of the case and control groups were described as mean standard deviation (SD) and compared using Students t-test for continuous variables. Genotype and allele frequencies were computed and checked for deviation from the HardyWeinberg equilibrium (ihg2.helmholtz-muenchen.de/cgi-bin/hw/hwa1.pl). Categorical variables were presented as proportions and were compared using the chi-square test or Fishers exact test (two-tailed). Further stratification of the patients based on sex and aneurysm rupture status was performed to understand the role of the VCAN variant within the sexes and between the ruptured aneurysm and non-ruptured aneurysm groups. The association of SNPs with the risk of sporadic IA was investigated using logistic regression analysis. Statistical significance was set at P<0.05. All statistical analyses were performed using GraphPad Prism 8.02 (San Diego, CA, USA) and SPSS software (version 21.0; IBM Corp., Armonk, NY, USA).
A total of 162 IA patients and 182 control subjects were included in this study. The demographic characteristics of patients and controls are shown in Table 1. In the case group, 72.8% of the patients had a single aneurysm. The aneurysms were primarily located in the internal carotid artery (38.3%), followed by the middle cerebral artery (19.1%), anterior communicating artery (13.6%), and other locations. Additional details are provided in Table 2.
Table 1 Characteristics of Cases vs Controls
Table 2 Clinical Characteristics of Intracranial Aneurysm
The distribution of the SNP genotypes was consistent with the HardyWeinberg equilibrium. As shown in Table 3, there were significant differences in the genotype and allele frequency distributions of rs251124 and rs173686 between the IA cases and controls (P<0.05). A significant association was observed with rs251124 at the allelic (OR=1.489, CI: 1.0892.044; P=0.0137) and genotypic (P=0.0415) levels. The frequency of rs251124-TT in IA patients was higher than in controls (2= 6.364, P=0.0415). The risk allele frequencies of rs173686 were significantly different between patients with IA and controls (OR=1.558, CI: 1.1152.171; P=0.0096). For SNP rs2287926, there was no statistically significant difference in genotype or allele frequencies between the patient and control groups (Table 3).
Table 3 Genotype and Allele Frequencies of SNPs of VCAN
Table 4 shows the genotypes of the SNPs and their associations with IA. Logistic regression analysis showed that the T/T genotype and T allele of rs251124 were independent risk factors for IA (OR=1.726, 95% CI: 1.1362.263; P=0.011). Similarly, for the SNP rs173686, G allele carriers were also at a significantly higher risk of IA (OR=2.52, 95% CI: 1.2615.037; P=0.009).
Table 4 Logistic Regression Model of Genotype Analysis
Table 5 shows no significant difference in genotype frequencies between the ruptured and unruptured aneurysm groups at either of the two SNPs rs251124 and rs173686 (P>0.05).
Table 5 Genotypic Results of Ruptured and Unruptured Aneurysms
Table 6 shows no significant difference in genotype frequencies among aneurysm groups at either of the two SNPs rs251124 and rs173686 (P> 0.05).
Table 6 Genotype Frequencies of SNPs rs251124 and rs173686 at Different Locations
Table 7 suggests that the rs251124 T allele and rs173686 G allele contribute to a significantly higher risk for males and females at both allelic and genotypic levels when stratified based on sex (P<0.05).
Table 7 Comparison of the Genotype and Allele Frequencies of rs251124 and rs173686 Within Males and Females in Cases and Control
There are various theories about the development of aneurysms, most of which reflect an imbalance in the ECM remodelling. ECM remodelling plays an important role in maintaining the structure and integrity of intracranial arteries and its reduction is a prominent feature of cerebral aneurysms. The VCAN gene localised on 5q12q14 has 15 exon codes9 for a large 372.82 kDa chondroitin sulphate proteoglycan found abundantly in the ECM and plays various roles in maintaining ECM functions. Some studies have shown that a decreased density of smooth muscle cells results in decreased production of CSPG2 (also known as versican), which in turn weakens the vascular wall. VCAN (CSPG2) also plays an important role in the assembly of ECM, and diminished maintenance of the ECM has been increasingly regarded as an important factor in the development of IA.16
This study investigated the associations between three SNPs in the VCAN gene and IA susceptibility in the Eastern Chinese population. The results showed that rs251124T/T genotype and T allele and rs173686 G/G genotype and G allele increased the risk of IA formation. No significant differences in genotype or allele frequencies between the case and control groups were detected at the rs2287926 SNP. Our findings further support the VCAN gene as an IA susceptibility gene.
The VCAN gene (also known as chondroitin sulphate proteoglycan [CSPG2]) predicts the risk of aneurysm development and subsequent rupture.12,15,16 Nevertheless, the association between the SNPs of VCAN and the risk of IA remains controversial due to contrary reports. For example, Sathyan et al10 found that the minor allele T of rs251124 showed an increased risk of IA. The CT genotype has been defined as a risk factor for the occurrence and rupture of aneurysms in a South Indian population. In addition, rs2287926 further substantiates the potential role of VCAN in the pathogenesis of IA.
Moreover, no confirmed association between rs173686 at genotypic and allelic levels and IA in the South Indian population has been reported. However, in a Dutch population, the VCAN (CSPG2) genes were identified as susceptibility genes for IA, and the rs173686 polymorphism has also been linked to IA.12 The association between the rs173686 polymorphism and IA risk has also been observed in a Kazakh population.14 Similarly, another study replicated the association of rs251124 with the risk of IAs in a Japanese IA population.15 In contrast, replication studies reported a lack of association between the CSPG2 variants (rs173686 and rs251124) with IA susceptibility.15 The above studies suggest that race and geography may influence these contradictory results. On the other hand, this may be explained by the heterogeneity of ethnic origin and/or small sample size.
Consistent with previous studies and meta-analyses,10,12,13 we found that rs251124 was associated with sporadic IAs, and rs251124T/T genotype and T allele were risk factors for IA in the Eastern Chinese population, but not in agreement with the results of Sun et al,15 who found no confirmed association in a study of Han Chinese. Additionally, our study found that the rs173686 G/G genotype and G allele significantly increased the risk of IA formation, which was similar to the results of studies conducted among European,12 Kazakh,13 and Japanese populations,14 but inconsistent with the results of Sun et al.15 The contrary results indicate that individuals from the same ethnic group also have different susceptibilities. Sun et al15 reported that the two SNPs rs173686 and rs251124 of the CSPG2 gene were not susceptible to IAs in Northern Chinese (Beijing) Han nationality. Alternatively, we observed that rs173686 and rs251124 highly increased the risk of IA formation in the Eastern Chinese population. To the best of our knowledge, the occurrence of IA is the result of the combined effects of genetic and environmental factors. One of the underlying causes of this discrepancy might be regional differences. Our research subjects included patients from eastern China; the possibility of different genetic backgrounds and surroundings caused by ethnic and regional differences might affect the experimental results. In addition, our study group was relatively small; therefore, our results require validation in a large-scale population. Overall, it has been hypothesised that genetic heterogeneity among diverse populations can lead to such paradoxical results.
In addition, our study included patients with ruptured and unruptured IAs. For either of the two SNPs rs173686 and rs251124, there was no statistically significant difference in genotype or allele frequencies between the two groups studied, suggesting that no associations were found in the SNPs rs173686 and rs251124 with IA rupture susceptibility in the Eastern Chinese population. To the best of our knowledge, this is the first study to investigate the association between the VCAN gene and IA rupture in a Chinese population.
Moreover, our study found no significant difference in genotype frequencies among aneurysm groups at either SNP rs251124 or rs173686 (P> 0.05). This suggests that the locations of aneurysm distribution may have nothing to do with SNP variation. Furthermore, subgroup analysis by sex showed that rs251124 T allele and rs173686 G allele contributed to high risk for both males and females at both allelic and genotypic levels, implying that sex has no significant effect on SNP variation. Another possible reason for this result is that the sample size was small.
This study had some limitations. It included only Eastern Chinese patients; therefore, the sample size was relatively small and may not be adequate for assessing the effect of these SNPs on the formation of IAs. Thus, additional studies using different populations are warranted to further validate ethnic and regional differences in the impact of the VCAN polymorphism on IA risk. Moreover, molecular biology experiments and reliable animal models are required to explore the specific mechanisms further.
This study revealed that rs251124 and rs173686 are genetic risk factors for IA formation in the Eastern Chinese population. No association was found between SNP rs2287926 and IA. Our findings suggest that the VCAN gene is an IA susceptible gene, which warrants further study as a screening marker for intracranial aneurysms.
The authors thank Key project of Education Department of Anhui Province (KJ2019A0096) and Huainan science and technology planning project (2016A26(3)) for supporting this work.
The authors report no conflicts of interest in this work.
1. Hitchcock E, Gibson WT. A review of the genetics of intracranial berry aneurysms and implications for genetic counseling. J Genet Couns. 2017;26(1):2131. doi:10.1007/s10897-016-0029-8
2. Boehme AK, Esenwa C, Elkind MS. Stroke risk factors, genetics, and prevention. Circ Res. 2017;120(3):472495. doi:10.1161/CIRCRESAHA.116.308398
3. Ruigrok YM, Rinkel GJ. From GWAS to the clinic: risk factors for intracranial aneurysms. Genome Med. 2010;2(9):61. doi:10.1186/gm182
4. Cho SM, Marquardt RJ, Rice CJ, et al. Cerebral microbleeds predict infectious intracranial aneurysm in infective endocarditis. Eur J Neurol. 2018;25(7):970975. doi:10.1111/ene.13641
5. Chen Y, Zhang Y, Chao YJ, et al. Stent-assisted coiling embolization of middle cerebral artery trifurcation wide-necked aneurysms. Eur Rev Med Pharmacol Sci. 2017;21(19):43464349.
6. Tromp G, Weinsheimer S, Ronkainen A, Kuivaniemi H. Molecular basis and genetic predisposition to intracranial aneurysm. Ann Med. 2014;46(8):597606. doi:10.3109/07853890.2014.949299
7. Bourcier R, Redon R, Desal H. Genetic investigations on intracranial aneurysm: update and perspectives. J Neuroradiol. 2015;42(2):6771. doi:10.1016/j.neurad.2015.01.002
8. Ruigrok YM, Rinkel GJ, Wijmenga C. Genetics of intracranial aneurysms. Lancet Neurol. 2005;4:179189. doi:10.1016/S1474-4422(05)70021-1
9. Iozzo RV, Naso MF, Cannizzaro LA, et al. Mapping of the versican proteoglycan gene (CSPG2) to the long arm of human chromosome 5 (5q125q14). Genomics. 1992;14(4):845851. doi:10.1016/S0888-7543(05)80103-X
10. Sathyan S, Koshy LV, Balan S, et al. Association of Versican (VCAN) gene polymorphisms rs251124 and rs2287926 (G428D), with intracranial aneurysm. Meta Gene. 2014;2:651660. doi:10.1016/j.mgene
11. Onda H, Kasuya H, Yoneyama T, et al. Genomewide-linkage and haplotype-association studies map intracranial aneurysm to chromosome 7q11. Am J Hum Genet. 2001;69(4):804819. doi:10.1086/323614
12. Ruigrok YM, Rinkel GJ, Wijmenga C. The versican gene and the risk of intracranial aneurysms. Stroke. 2006;37(9):23722374. doi:10.1161/01.STR.0000236499.55301.09
13. Zholdybayeva EV, Medetov YZ, Aitkulova AM, et al. Genetic risk factors for intracranial aneurysm in the Kazakh population. J Mol Neurosci. 2018;66(1):135145. doi:10.1007/s12031-018-1134-y
14. Ruigrok YM, Rinkel GJ, Wijmenga C, et al. Association analysis of genes involved in the maintenance of the integrity of the extracellular matrix with intracranial aneurysms in a Japanese cohort. Cerebrovasc Dis. 2009;28(2):131134. doi:10.1159/000223438
15. Sun H, Zhang D, Zhao J. Chondroitin sulfate proteoglycan 2 (CSPG2) gene polymorphisms rs173686 and rs251124 are not associated with intracranial aneurysms in Chinese Han nationality. Ups J Med Sci. 2007;112(3):289295. doi:10.3109/2000-1967-201
16. Ruigrok YM, Rinkel GJ, Vant Slot R, et al. Evidence in favor of the contribution of genes involved in the maintenance of the extracellular matrix of the arterial wall to the development of intracranial aneurysms. Hum Mol Genet. 2006;15:33613368. doi:10.1093/hmg/ddl412
Read the rest here:
SNPs rs251124, rs2287926, and rs173686 with IA | NDT - Dove Medical Press
- BENITEC BIOPHARMA INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q) - Marketscreener.com - February 13th, 2023 [February 13th, 2023]
- CENTOGENE to Participate in Upcoming Conferences in February in the Lead Up to Rare Disease Day - Marketscreener.com - February 7th, 2023 [February 7th, 2023]
- Gene | Definition, Structure, Expression, & Facts | Britannica - January 27th, 2023 [January 27th, 2023]
- New gene therapy delivers treatment directly to brain - January 27th, 2023 [January 27th, 2023]
- Indian Pharma Congress: Gene-cell therapy, preventive medicine future of health care, says expert - Economic Times - January 25th, 2023 [January 25th, 2023]
- A blood test that identifies people at higher risk of miscarriage? Thats the goal of this award-winning Rutgers med student. - The Philadelphia... - January 19th, 2023 [January 19th, 2023]
- Gene Therapy: Genes As Medicine | Pfizer - January 6th, 2023 [January 6th, 2023]
- How Genomics will ensure a risk-free and beneficial treatment for good health and well-being - The Financial Express - December 28th, 2022 [December 28th, 2022]
- Regenerative Medicine Advanced Therapy Designation | FDA - December 18th, 2022 [December 18th, 2022]
- 3576 - Gene ResultCXCL8 C-X-C motif chemokine ligand 8 [ (human)] - November 23rd, 2022 [November 23rd, 2022]
- Study identifies new gene that drives colon cancer - EurekAlert - October 17th, 2022 [October 17th, 2022]
- Updated Stroke Gene Panels: Rapid evolution of knowledge on monogenic causes of stroke | European Journal of Human Genetics - Nature.com - October 17th, 2022 [October 17th, 2022]
- The challenges of translating CRISPR to the clinic - Labiotech.eu - October 17th, 2022 [October 17th, 2022]
- Editas Medicine Presents Preclinical Data on EDIT-103 for Rhodopsin-associated Autosomal Dominant Retinitis Pigmentosa at the European Society of Gene... - October 17th, 2022 [October 17th, 2022]
- 'We have to find a way': FDA seeks solutions to aid bespoke gene therapy - BioPharma Dive - October 17th, 2022 [October 17th, 2022]
- Mathematical model could bring us closer to effective stem cell therapies - Michigan Medicine - October 17th, 2022 [October 17th, 2022]
- Approval, Commercialization Highlighted at Cell & Gene Meeting on the Mesa - Genetic Engineering & Biotechnology News - October 17th, 2022 [October 17th, 2022]
- CANbridge-UMass Chan Medical School Gene Therapy Research in Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 29th Annual... - October 17th, 2022 [October 17th, 2022]
- Depression Treatment: How Genetic Testing Can Help Find the Right Medication - Dunya News - October 17th, 2022 [October 17th, 2022]
- The Risk-Reward Proposition for CGT Clinical Trials - Applied Clinical Trials Online - October 17th, 2022 [October 17th, 2022]
- Precision Medicine Could Get Even More Precise With Allarity Therapeutics Next-Generation Diagnostics - Benzinga - October 17th, 2022 [October 17th, 2022]
- Decibel Therapeutics Receives FDA Clearance of IND Application for DB-OTO, a Gene Therapy Product Candidate Designed to Provide Hearing to Individuals... - October 17th, 2022 [October 17th, 2022]
- Time for your medicine: unlocking the power of our body clocks - The Guardian - October 17th, 2022 [October 17th, 2022]
- Replay establishes distinguished Scientific Advisory Board of genomic medicine and cell therapy experts - Yahoo Finance - October 17th, 2022 [October 17th, 2022]
- Scientists Reappraise the Role of Zombie Cells That Anti-aging Medicine Has Sought to Eliminate - Neuroscience News - October 17th, 2022 [October 17th, 2022]
- Forge Biologics Announces Updated Positive Clinical Data in RESKUE, a Novel Phase 1/2 Gene Therapy Trial for Patients with Krabbe Disease - Business... - October 17th, 2022 [October 17th, 2022]
- Gene Expression Signatures Are Analyzed for Biomarkers of Response in HCC - Targeted Oncology - October 17th, 2022 [October 17th, 2022]
- NHS England World-first national genetic testing service to deliver rapid life-saving checks for babies and kids - NHS England - October 17th, 2022 [October 17th, 2022]
- The proteinprotein relationship that could mend a broken heart - RegMedNet - October 17th, 2022 [October 17th, 2022]
- Study finds microprotein correlated to Alzheimers risk - Daily Trojan Online - October 11th, 2022 [October 11th, 2022]
- Passage Bio Announces Appointment of William Chou, M.D. as Chief Executive Officer - Yahoo Finance - October 11th, 2022 [October 11th, 2022]
- Gene Therapy Rapidly Improves Night Vision in Adults with Congenital Blindness - Newswise - October 11th, 2022 [October 11th, 2022]
- Scientists Discover Protein Partners that Could Heal Heart Muscle | Newsroom - UNC Health and UNC School of Medicine - October 11th, 2022 [October 11th, 2022]
- The Pros and Cons of Lentiviral and Adeno-Associated Viral Vectors - The Medicine Maker - October 11th, 2022 [October 11th, 2022]
- Insights & Outcomes: Foreign DNA, quantum potholes and relapsing fever - Yale News - October 11th, 2022 [October 11th, 2022]
- Expediting IND applications with drug master files - BioPharma Dive - October 11th, 2022 [October 11th, 2022]
- UNC School of Medicine Awarded $3 Million to Lead Study to Reduce PTSD Frequency, Severity | Newsroom - UNC Health and UNC School of Medicine - October 11th, 2022 [October 11th, 2022]
- Lineage to Present at Alliance for Regenerative Medicine 2022 Cell & Gene Meeting on the Mesa - businesswire.com - October 8th, 2022 [October 8th, 2022]
- The Next Crispr Gene Editing IPO Could Be Near - Henry Herald - October 8th, 2022 [October 8th, 2022]
- 10-year CRISPR anniversary: How gene editing revolutionized medicine, and what lies ahead - Genetic Literacy Project - October 8th, 2022 [October 8th, 2022]
- Blood from a baby at birth can be gene sequenced to prevent diseases - USA TODAY - October 8th, 2022 [October 8th, 2022]
- What doctors wish patients knew about breast-cancer prevention - American Medical Association - October 8th, 2022 [October 8th, 2022]
- Growth in Cell and Gene Therapy Market - Pharmaceutical Technology Magazine - October 8th, 2022 [October 8th, 2022]
- Gene Editing Service Market 2022 : Top Players to Reflect Impressive Growth Rate till 2029: Caribou Biosciences, CRISPR Therapeutics, Merck KGaA,... - October 8th, 2022 [October 8th, 2022]
- Tip Sheet: $78 million to support new precision oncology institute, update on experimental gene therapy for herpes and the launch of Fred Hutch's new... - October 8th, 2022 [October 8th, 2022]
- Cell and Gene Therapy: Rewriting the Future of Medicine - Technology Networks - October 2nd, 2022 [October 2nd, 2022]
- Growth in Cell and Gene Therapy Market - BioPharm International - October 2nd, 2022 [October 2nd, 2022]
- CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX130 for the Treatment of Cutaneous T-Cell... - October 2nd, 2022 [October 2nd, 2022]
- BioMarin Resubmits Biologics License Application (BLA) for Valoctocogene Roxaparvovec AAV Gene Therapy for Severe Hemophilia A to the FDA - PR... - October 2nd, 2022 [October 2nd, 2022]
- Fighting Breast and Ovarian Cancer With a Lupus Antibody - Yale School of Medicine - October 2nd, 2022 [October 2nd, 2022]
- This gene therapy company is testing new tech to 'switch off' diabetes and obesity with a pill - Euronews - October 2nd, 2022 [October 2nd, 2022]
- Tenaya Therapeutics to Participate in Inaugural Hypertrophic Cardiomyopathy Medical Societys 2022 Scientific Sessions - Yahoo Finance - October 2nd, 2022 [October 2nd, 2022]
- Risk of Alzheimer's dementia may be predicted with help of new tool Washington University School of Medicine in St. Louis - Washington University... - October 2nd, 2022 [October 2nd, 2022]
- Tiny Sea Creature's Genes Shed Light on Evolution of Immunity - UPMC - October 2nd, 2022 [October 2nd, 2022]
- Who will get the call from Stockholm? It's time for STAT's 2022 Nobel Prize predictions - STAT - October 2nd, 2022 [October 2nd, 2022]
- Excision BioTherapeutics Awarded California Institute for Regenerative Medicine (CIRM) Grant to Support Ongoing Phase 1/2 Trial Evaluating EBT-101 as... - October 2nd, 2022 [October 2nd, 2022]
- NeuroVoices: Emma Ciafaloni, MD, on the Vast Expansion of Innovative Approaches to Duchenne Muscular Dystrophy - Neurology Live - October 2nd, 2022 [October 2nd, 2022]
- COVID mRNA Jabs and Testing Kicked Off This Industry of Drug Development: Here's What You Need to Know - The Epoch Times - October 2nd, 2022 [October 2nd, 2022]
- Kidney resident macrophages have distinct subpopulations and occupy distinct microenvironments - University of Alabama at Birmingham - October 2nd, 2022 [October 2nd, 2022]
- Nobel Prize for medicine: the full list of winners - The National - October 2nd, 2022 [October 2nd, 2022]
- The surprising link between circadian disruption and cancer may have to do with temperature - EurekAlert - October 2nd, 2022 [October 2nd, 2022]
- The global live cell imaging market is expected to grow at a CAGR of 8.44% during 2022-2027 - Yahoo Finance - October 2nd, 2022 [October 2nd, 2022]
- Chroma Medicine Announces Formation of Scientific Advisory Board of Global Experts in Gene Editing and Cell and Gene Therapy - PR Newswire - September 20th, 2022 [September 20th, 2022]
- Ring Therapeutics Announces Issuance of U.S. Patent for its Anellovector Compositions - Yahoo Finance - September 20th, 2022 [September 20th, 2022]
- Cholesterol gene mutation: Why would a healthy 27-year-old have severe heart problems? - 69News WFMZ-TV - September 20th, 2022 [September 20th, 2022]
- Gene Therapy for Severe Hemophilia B Could Be More Cost Effective Than Current Treatments - Managed Healthcare Executive - September 20th, 2022 [September 20th, 2022]
- AVROBIO Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration (FDA) for First Gene Therapy in Development for Cystinosis... - September 20th, 2022 [September 20th, 2022]
- The Biggest CGT Breakthroughs Through the Eyes of Our 2022 Power List - The Medicine Maker - September 20th, 2022 [September 20th, 2022]
- Leading Virus Researcher to Chair UVA's Department of Microbiology, Immunology and Cancer Biology - UVA Health Newsroom - September 20th, 2022 [September 20th, 2022]
- Work remains on Tay-Sachs and other Ashkenazi genetic disorders J. - The Jewish News of Northern California - September 20th, 2022 [September 20th, 2022]
- Study Shows Genetic Link to Moving to the Beat of Music - Newswise - September 20th, 2022 [September 20th, 2022]
- Viewpoint: In the post Roe v Wade world, what changes should a biology textbook writer make to address the medical repercussions of Dobbs? - Genetic... - September 20th, 2022 [September 20th, 2022]
- Alnylam Receives Approval in Europe for AMVUTTRA (vutrisiran) for the Treatment of Hereditary Transthyretin-mediated (hATTR) Amyloidosis in Adult... - September 20th, 2022 [September 20th, 2022]
- CSL flexes gene therapy muscle with latest drug - Sydney Morning Herald - September 20th, 2022 [September 20th, 2022]
- The MIT Press releases new book on the science of the heart from cardiac expert Dr. Sian Harding - EurekAlert - September 20th, 2022 [September 20th, 2022]
- Global Pharmaceutical Contract Manufacturing Market is projected to reach a market value of US$329.7 Billion in 2032: Visiongain Reports Ltd - Yahoo... - September 20th, 2022 [September 20th, 2022]
- Alzheon Reports Industry-Leading Biomarker, Brain Preservation and Clinical Effects Following 12 Months of Treatment in Phase 2 Trial of Oral ALZ-801... - September 20th, 2022 [September 20th, 2022]
- Do You Have Lung Cancer With An EGFR Mutation? If So, The Drug Tagrisso Might Be Right For You Based On New Results From A 'Practice Changing' Trial -... - September 20th, 2022 [September 20th, 2022]
- Getting rid of unwanted transformed cells: Possible new directions in cancer therapy - EurekAlert - September 20th, 2022 [September 20th, 2022]
- Sven Kili on reconvening with the ISCT - The Medicine Maker - September 14th, 2022 [September 14th, 2022]